Sunshine Biopharma (NASDAQ: SBFM) lowers Series B warrant price to $1.2202
Rhea-AI Filing Summary
Sunshine Biopharma Inc. reports that, as a result of recent sales of its common stock under a previously disclosed at-the-market offering, the exercise price of its outstanding Series B Warrants has been reduced to $1.2202. This exercise price remains subject to further adjustment under the terms of the Series B Warrants.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Series B Warrant exercise price: $1.2202
Report date: August 3, 2026
2 metrics
Series B Warrant exercise price
$1.2202
Exercise price after adjustment due to recent at-the-market common stock sales
Report date
August 3, 2026
Date on which the company reported the Series B Warrant exercise price adjustment
Key Terms
at-the-market offering, Series B Warrants, Emerging growth company
3 terms
at-the-market offering financial
"recent sales of common stock under the Company’s previously disclosed at-the-market offering"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
Series B Warrants financial
"the exercise price of the Company’s outstanding Series B Warrants has been reduced"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What change did Sunshine Biopharma (SBFM) disclose regarding its Series B Warrants?
Sunshine Biopharma Inc. disclosed that the exercise price of its outstanding Series B Warrants has been reduced to $1.2202. This change follows recent sales of the company’s common stock under a previously disclosed at-the-market offering, which triggered the adjustment mechanism in the warrant terms.
Why was the Series B Warrant exercise price adjusted for Sunshine Biopharma (SBFM)?
The adjustment was triggered by recent sales of Sunshine Biopharma’s common stock under a previously disclosed at-the-market offering. Those equity sales activated anti-dilution provisions in the Series B Warrants, requiring the exercise price to be reset according to the formula in the warrant terms.
What is the new exercise price of Sunshine Biopharma (SBFM) Series B Warrants?
The new exercise price of Sunshine Biopharma’s outstanding Series B Warrants is $1.2202. This figure reflects the pricing adjustment that became effective after recent sales of the company’s common stock through its previously disclosed at-the-market offering to investors in the market.
Can the Series B Warrant exercise price change again for Sunshine Biopharma (SBFM)?
Yes. The company states that the $1.2202 exercise price is still subject to further adjustment under the terms of the Series B Warrants. Future changes could occur if additional events specified in those warrant provisions trigger further anti-dilution or price-reset mechanisms.
When did Sunshine Biopharma (SBFM) report the Series B Warrant price reduction?
The company reports the Series B Warrant exercise price reduction as effective as of the date of the report, which is dated August 3, 2026. This timing links the adjustment to recent common stock sales completed before that reporting date.